User talk:Chefmikesf/sandbox/Johnson & Johnson

New COVID-19 Content
Request: Hi! I'm posting here on behalf of Johnson & Johnson, a company I have declared my COI. The article currently has no mention of Johnson & Johnson and its companies participation with the COVID-19 global pandemic. When you research COVID-19 online there are many secondary sources about its contributions. In my research, the events outlined below are the notable for inclusion in the article.

Content about the request: Below is the proposed material to publish on the article. The subtitle above each section is a subsection in the History section. I'm proposing adding the new content below the existing paragraphs in the sections.

Indefensible and XyZAn do you have the interest to review this proposal? Open to ideas and suggestions too. Thank you--Chefmikesf (talk) 02:26, 23 April 2020 (UTC)

1.

1959: McNeil Consumer Healthcare:

Demand for the product Tylenol surged two to four times normal levels in March 2020 during the COVID-19 pandemic. In response, the company increased production globally. For example, the Tylenol plant in Puerto Rico ran 24 hours a day, seven days a week.

2.

1961: Janssen Pharmaceuticals:

Janssen Pharmaceuticals, in partnership with Beth Israel Deaconess Medical Center (BIDMC), is developing a vaccine candidate for COVID-19, based on the same technology used to make its Ebola vaccine. September 2020, the vaccine candidate is prepared to enter phase 1 human clinical study.

3.

Ethicon, Inc.:

In response to the shortage of ventilators during the COVID-19 pandemic, Ethicon, with Prisma Health, made and distributed the VESper Ventilator Expansion Splitter. Using 3D printing technology, the product is used to expand the capacity of one ventilator to support two patients.

4.

2010 onwards:

Johnson & Johnson committed over $1 billion toward development of a COVID-19 not-for-profit vaccine in partnership with the Biomedical Advanced Research and Development Authority (BARDA) Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS). In a Sky News interview, Dr. Paul Stoffels, M.D.,  Johnson & Johnson Chief Scientific Officer and Vice Chairman of the Executive Committee said, “In order to go fast, Johnson & Johnson - the people of Johnson & Johnson - are committed to do this and all together we say we're going to do this not for profit. That's the fastest and the best way to find all the collaborations in the world to make this happen so we commit to bring this at a not-for-profit level."

Update Corporate governance and Infobox
Hi! I'm posting here on behalf of Johnson & Johnson, a company I have declared my COI. I noticed some inaccuracies and omissions in the Infobox and Corporate governance sections. Below are the suggested improvements to each part of the article. Let me know if there are any questions!--Chefmikesf (talk) 22:07, 3 June 2020 (UTC)

1.

Reason and Request: Reason and Request: Please update the Corporate governance section with the additions in Proposed Corporate governance content. The Corporate governance section is missing key members of the Board of Directors and Executive Leadership Team. The proposed version includes current information for the company. Please see the references used on the article. These references include the missing members of each respective committee.

Current Corporate governance content

Current members of the board of directors of Johnson & Johnson for 2019 are: Alex Gorsky, Mary C. Beckerle, D. Scott Davis, Ian E. L. Davis, Jennifer A. Doudna, Mark B. McClellan, Anne M. Mulcahy, William D. Perez, Charles Prince, A. Eugene Washington, Marillyn A. Hewson, Ronald A. Williams, and Mark Weinberger.

Current members of Executive Committees of Johnson & Johnson are: Joseph Wolk (the company's chief financial officer), Peter Fasolo, Paul Stoffels, and Michael Sneed.

On July 2, 2018, Johnson & Johnson's head of pharmaceuticals, Joaquin Duato, became the vice chairman of the executive committee.

Proposed Corporate governance content

Current members of the board of directors of Johnson & Johnson for 2019 are: Alex Gorsky, Mary C. Beckerle, D. Scott Davis, Ian E. L. Davis, Jennifer A. Doudna, Mark B. McClellan, Anne M. Mulcahy, William D. Perez, Charles Prince, A. Eugene Washington, Marillyn A. Hewson, Hubert Joly, and Ronald A. Williams.

Current members of Executive Committees of Johnson & Johnson are: Joseph Wolk (the company's chief financial officer), Peter Fasolo, Ashley McEvoy, Thibaut Mongon, Paul Stoffels, Michael Sneed, Jennifer Taubert, Michael Ullmann, and Kathy Wengel.

On July 2, 2018, Johnson & Johnson's head of pharmaceuticals, Joaquin Duato, became the vice chairman of the executive committee.

1.

Reason and Request: The Infobox section has inaccuracies and is missing key content. Please consider replacing each section of the Infobox with the proposed replacement.

Update Consumer Healthcare

| industry = Pharmaceutical Medical devices Consumer Healthcare

Add Key People

| key_people = Alex Gorsky (Chairman and CEO) Paul Stoffels (Vice Chairman of the Executive Committee and Chief Scientific Officer) Joaquin Duato (Vice Chairman of the Executive Committee

'''Remove Brands from subsidiaries. Add subsidiaries with Wikipedia articles'''

| subsid = Janssen Pharmaceutica Janssen Biotech Ortho-McNeil Pharmaceutical Ortho-McNeil-Janssen Ortho Pharmaceutical    Johnson  & Johnson Pharmaceutical Research and Development Crucell Cilag Tibotec Actelion Alza MorphoSys Ethicon Inc. DePuy Synthes Synthes Acclarent Mentor (company) Johnson & Johnson Vision McNeil Consumer Healthcare

1873-1885: Before Johnson & Johnson
Robert Wood Johnson began his professional training as a pharmaceutical apprentice. Johnson co-founded his own company with George Seabury in 1873. The New York-based Seabury & Johnson became known for its medicated plasters. Robert Wood Johnson represented the company at the 1876 World's Fair.  There he heard Dr. Joseph Lister’s explanation of a new procedure: antiseptic surgery. Johnson parted ways with his business partner, Seabury in 1885.

1886: Founding of Johnson & Johnson
Robert Wood Johnson joined his brothers, James Wood Johnson and Edward Mead Johnson and created a line of ready-to-use sterile surgical dressings in 1886. They founded Johnson & Johnson in 1886 with 14 employees, eight women and six men, manufacturing sterile surgical supplies, household products, and medical guides. Those products initially featured a logo that resembled the signature of James Wood Johnson, very similar to the current logo. Robert Wood Johnson served as the first president of the company. Upon his death in 1910, he was succeeded by his brother James Wood Johnson. Robert Wood Johnson II became president of the company in 1932.

1887-1942: Early History
The company sold medicated plasters such as Johnson & Johnson's Black Perfect Taffeta Court Plaster and also manufactured the world’s first sterile surgical products, including sutures, absorbent cotton, and gauze. Johnson & Johnson published Modern Methods of Antiseptic Wound Treatment, a guide on how to do sterile surgery using its products, and in 1888, distributed 85,000 copies to doctors and pharmacists across the United States. The manual was translated into three languages and distributed worldwide. The first commercial First Aid Kit was designed in 1888 to support railroad construction workers, who were often hundreds of miles from medical care. The kits included antiseptic emergency supplies and directions for field use. In 1901, Johnson & Johnson published the Handbook of First Aid, a guide on applying first aid. In 1889, the company hired pharmacist Fred Kilmer as its first scientific director, who led its scientific research and wrote educational manuals. Kilmer was employed at Johnson & Johnson until 1934. Kilmer’s first achievement as scientific director was developing the industrial sterilization process. Johnson & Johnson had more than 400 employees and 14 buildings by 1894. In 1894, the company began producing Johnson’s Baby Powder, the company’s first baby product. Robert Wood Johnson's granddaughter, Mary Lea Johnson Richards, was the first baby to appear on a Johnson & Johnson baby powder label.

The company introduced the world’s first Maternity kit in 1894 to aid at-home births. The kit contained antiseptic soap, sanitary napkins, umbilical tape, and Johnson’s Baby Powder. The products were later marketed separately, including Lister’s Towels, which was the world’s first mass-produced sanitary napkin. Kilmer wrote Hygiene in Maternity, an instructional guide for mothers before and after delivery. In 1904, the company expanded its baby care products with Lister’s Sanitary Diapers, a diaper product for Infants. During the Spanish American War, Johnson & Johnson developed and donated 300,000 packaged compressed surgical dressings for soldiers in the field and created a trauma stretcher for field medics. Johnson & Johnson donated its products in disaster relief efforts of the 1900 Galveston hurricane and the 1906 San Francisco earthquake. Johnson & Johnson vaccinated all of its employees against smallpox during the 1901 smallpox epidemic. Johnson & Johnson employed more than 1,200 people by 1910. Women comprised of half of the Johnson & Johnson workforce and led a quarter of Johnson & Johnson’s departments. During World War I, Johnson & Johnson factories increased production to meet wartime demands for sterile surgical products. In 1916, the company acquired Chicopee Manufacturing Company in Chicopee Falls, Massachusetts to meet demand. Near the end of World War I, the 1918 flu pandemic broke out. The company invented and distributed an epidemic mask which helped prevent the spread of the flu.

In 1919, Johnson & Johnson opened the Gilmour Plant near Montreal, its first factory outside of the United States, which produced surgical products for international customers. In 1924, Slough, England was the company’s first overseas manufacturing facility. In 1920, Earle Dickson combined two Johnson & Johnson products, adhesive tape and gauze, to create the first commercial adhesive bandage. Band-Aid Brand Adhesive Bandages began sales the following year. In 1921, the company released Johnson’s Baby Soap. Named after its Massachusetts facility, Johnson & Johnson built a textile mill and company town, Chicopee, outside of Gainesville, Georgia. In the 1930s, the company expanded operations to Argentina, Brazil, Mexico, and South Africa. In 1931, Johnson & Johnson introduced the first prescription contraceptive gel marketed as Ortho-Gynol.

During The Great Depression Johnson & Johnson kept all its workers employed and raised wages by five percent. In 1933, Robert Wood Johnson II wrote a letter, Dear Mr. President, to Franklin D. Roosevelt, calling for a federal law to increase wages and reduce hours for all American workers. The company also opened a new facility in Chicago during that period. Johnson wrote and distributed Try Reality: A Discussion of Hours, Wages, and The Industrial Future to persuade business leaders to follow his lead, advocating that business is more than profit and that companies have responsibilities to consumers, employees, and society. In Try Reality, the section titled “An Industrial Philosophy” would later become Our Credo. In 1935, Johnson’s Baby Oil was added to its line of baby products. Both male and female Johnson & Johnson employees were drafted and enlisted during World War II. The company ensured no one would lose their job when they returned home. Robert Wood Johnson II was appointed head of the Smaller War Plants Corporation in Washington, D.C. His work ensured U.S. factories with under 500 employees were awarded government contracts.

Updates to the COVID-19 content
Hello, The Covid-19 section on the article became unorganized lately. First, the Momenta Pharmaceuticals content is irrelevant to this COVID-19 subsection and the content already exists in the 2010 onwards subsection. I suggest removing it from the COVID-19 subsection. Second, I see two distinct themes with the content. The company made an initial response to the pandemic. They developed the Ad26.COV2.S vaccine. I suggest breaking the subsection into two subsections, seen below, COVID-19 response and COVID-19 vaccine.

Grand'mere Eugene, what are your thoughts on my sandbox excerpt below? Would you be open to make these updates?

Coronavirus (COVID-19) response
Johnson & Johnson committed over $1 billion toward the development of a not-for-profit COVID-19 vaccine in partnership with the Biomedical Advanced Research and Development Authority (BARDA) Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS). Paul Stoffels of Johnson & Johnson said, "In order to go fast, the people of Johnson & Johnson are committed to do this and all together we say we're going to do this not for profit. That's the fastest and the best way to find all the collaborations in the world to make this happen so we commit to bring this at a not-for-profit level."

Janssen Vaccines, in partnership with Beth Israel Deaconess Medical Center (BIDMC), is responsible for developing the vaccine candidate, based on the same technology used to make its Ebola vaccine. The vaccine candidate is expected to enter phase 1 human clinical study in September 2020.

Demand for the product Tylenol surged two to four times normal levels in March 2020. In response, the company increased production globally. For example, the Tylenol plant in Puerto Rico ran 24 hours a day, seven days a week.

In response to the shortage of ventilators, Ethicon, with Prisma Health, made and distributed the VESper Ventilator Expansion Splitter, which uses 3D printing technology, to allow one ventilator to support two patients.

Coronavirus (COVID-19) vaccine
In April 2020, Johnson & Johnson entered a partnership with Catalent who will provide large-scale manufacturing of J&J's vaccine at Catalent's Bloomington facility. The partnership was expanded to include Catalent's Italian facility in July 2020.

In June 2020, Johnson & Johnson and the National Institute of Allergy and Infectious Diseases (NIAID) confirmed its intention to start a clinical trials of J&J's vaccine in September 2020, with the possibility of Phase 1/2a human clinical trials starting at an accelerated pace in the second half of July.

In July 2020, Johnson & Johnson pledged to deliver up to 300 million doses of its vaccine to the U.S., with 100 million upfront and an option for 200 million more. The deal, worth more than $1 billion, will be funded by the Biomedical Advanced Research and Development Authority (BARDA) and the U.S. Defense Department.

On 5 August 2020, the US government agreed to pay more than $1 billion to Johnson and Johnson (medical device company) for the production of 100 million doses of COVID-19 vaccine. As part of the agreed-upon deal, the U.S. can order up to 200 million additional doses of SARS-CoV-2 vaccine.

In September 2020, Johnson & Johnson started its 60,000-person phase 3 adenovirus-based vaccine trial. The trial was paused on October 12, 2020, because a volunteer became ill, but the company said it found no evidence that the vaccine had caused the illness and announced on October 23, 2020, that it would resume the trial.

In September 2020, Grand River Aseptic Manufacturing agreed with Johnson & Johnson, to support the manufacture of its SARS-CoV-2 vaccine candidate, including technology transfer and fill and finish manufacture.

JNJ COVID-19 Vaccine content additions
Hello, I noticed your post about renaming the article. The post also inspired a few ideas to improve the accessibility to related information such as Adenovirus vaccines and the JNJ/Janssen clinical protocol. These suggestions are based on []'s decision to model the Johnson & Johnson COVID-19 vaccine article with other COVID-19 vaccine articles.

Below are the concepts. What are your thoughts ?

1. Add a See also section to the article after the Deployment and impact section, then add two links to the proposed See also section.
 * Adenovirus vaccine
 * Adenoviridae

2. Add two links to the External links section.
 * Johnson & Johnson’s clinical protocol
 * Global information about Johnson & Johnson COVID-19 vaccine

3. Add Johnson & Johnson COVID-19 vaccine article link to the Johnson & Johnson Template box in the "Related section". Chefmikesf (talk) 20:45, 25 February 2021 (UTC)

Johnson & Johnson Business Sectors proposed sandbox
Below is the request broken into two parts. In the collapsible content box, I have the proposed new the Business Sectors section. Second, I outlined the steps to update the article, so the Structure and Products section are merged into one section that follows the History, and removes the unsourced content from the article. What are your thoughts on this?--

Proposed actions to update the section:
 * 1)   Rename the Structure section to Business Sectors.
 * 2) 	Update sentence one to the proposed sentence in the collapsible content box.
 * 3) 	Update the table to the proposed table in the sandbox.
 * 4) 	Remove the Unsourced Structure section content and tree chart.
 * 5) 	Remove paragraph one of products section. Contains the same information of in the Business Sectors section.
 * 6) 	Remove paragraph one of the pharmaceutical subsection. The content lacks sufficient sources and is outdated.
 * 7) 	Move paragraph two of the pharmaceutical subsection to the Janssen section of the History section.
 * 8) 	Move paragraph three and four of the pharmaceutical subsection to the pharmaceutical subsection of Business Sectors.
 * 9) 	Merge the last sentence in the 2010-onward section of the article.
 * 10) 	Remove the unsourced Medical Devices subsection.
 * 11) 	Remove the unsourced Consumer Health subsection.
 * 12) 	Remove the Products section heading.

Business Sectors

The company's business is divided into three major Business Sectors, Pharmaceuticals, Medical Devices, and Consumer Health. In 2020, these segments contributed 55%, 28%, and 17%, respectively, of the company's total revenues.

Pharmaceuticals

The company's major franchises in the Pharmaceuticals segment include Immunology, Neuroscience, Infectious Disease and Vaccines, Oncology, Cardiovascular and Metabolism, and Pulmonary Hypertension.

Medical Devices

The company's major franchises in the Medical Devices segment include Interventional Solutions, Orthopaedics, Surgery (General & Advanced), and Vision.

Consumer Health

The company's major franchises in the Consumer Health segment include Immunology, Cardiovascular & Metabolic Disease, Pulmonary Hypertension, Infectious Diseases & Vaccines, Neuroscience, and Oncology.

--Chefmikesf (talk) 23:51, 18 March 2021 (UTC)

2021 minor updates
Hi Grand'mere Eugene, Hope all is well. I noticed a few factual updates on the article based on 2020 numbers. What do you think about these?

Second, the subsection we added to the COVID-19 section were reverted. What are your thoughts on this?--Chefmikesf (talk) 19:39, 18 June 2021 (UTC)


 * Location: Infobox


 * Current Content:
 * num_employees = 132,200 (2019)
 * Proposed Content:
 * num_employees = 134,500 (2020)


 * Location: Lead

Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 37 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.
 * Current Content:

Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue.
 * Proposed Content:

Chefmikesf (talk) 17:21, 17 June 2021 (UTC)

JNJ Split-off Content
1. Reason and Request: Lead is inaccurate and out of date.

Current Lead: Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average, and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

Johnson & Johnson is headquartered in New Brunswick, New Jersey, the consumer division being located in Skillman, New Jersey. The corporation includes some 250 subsidiary companies with operations in 60 countries and products sold in over 175 countries. Johnson & Johnson had worldwide sales of $93.8 billion during the calendar year 2021.

The company announced in November 2021 that it would split into two publicly traded companies: one focused on consumer products and the other on pharmaceuticals and medical technologies.

Proposed Lead:

Johnson & Johnson (J&J) is an American multinational, pharmaceutical, and medical technologies corporation headquartered in New Brunswick, New Jersey and publicly traded on the New York Stock Exchange. Its common stock is a component of the Dow Jones Industrial Average, and the company is ranked No. 40 on the 2023 Fortune 500 list of the largest United States corporations. Johnson and Johnson has a global workforce of approximately 130,000 employees who are led by the company’s current chairman and chief executive officer, Joaquin Duato.

Johnson & Johnson was founded in in 1886, by three brothers Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson selling ready-to-use sterile surgical dressings. In 2023, the company split off its consumer healthcare business group into a new publicly traded company, Kenvue. The company is exclusively focused on developing and producing pharmaceutical prescription drugs and medical device technologies.

Johnson & Johnson is one of the world's most valuable companies and is one of only two U.S.-based companies that has a prime credit rating of AAA.

2.

Reason and Request:Recent split-off changed the company's structure. Please update the Business sectors according to these suggestions.

1. Business Sectors, Sentence One and Two: Update to one sentence.

The company's business is divided into two business sectors: Pharmaceuticals and Medtech.

2. Remove the Consumer Healthcare (1888-2023) section entirely. Add a new paragraph to the History 2000-present section to highlight the history of the Consumer Healthcare Business Sector separation.

3. Add to History, 2000-present section: Johnson & Johnson began the separation of their consumer healthcare business group in November 2021. In September 2022, Johnson & Johnson chose Kenvue as the new name for its Consumer Health business. Kenvue went public through an IPO in May 2023, with Johnson & Johnson maintaining a controlling stake of around 91 percent. On July 24th, 2023, Johnson & Johnson Launched an exchange offer to split-off Kenvue. Following the completion of the exchange offer, Johnson & Johnson will retain approximately 9.5% of the outstanding shares of Kenvue common stock.

2022 Factual Updates
Hi! I'm posting here on behalf of Johnson & Johnson, a company I have declared my COI. I noticed some inaccuracies and omissions in the Infobox and Corporate governance sections. Below are the suggested improvements to each part of the article. Let me know if there are any questions!--

1.

Reason and Request: The last sentence in the lead paragraph is inaccurate.

Existing Lead Paragraph sentence The company announced in November 2021 that it would split into two publicly traded companies: one focused on consumer products and the other on pharmaceuticals.

Proposed Lead Paragraph sentence update

The company announced in November 2021 that it would split into two publicly traded companies: one focused on consumer products and the other on pharmaceuticals and medical technologies.

2.

Reason and Request:

Please update the Corporate governance section with the additions in Proposed Corporate governance content. The Corporate governance section is missing key members of the Board of Directors and Executive Leadership Team. The proposed version includes current information for the company. Please see the references used on the article. These references include the missing members of each respective committee.

Proposed Corporate governance content

The current members of the board of directors of Johnson & Johnson for 2022 are: Mary C. Beckerle; D  Scott Davis; Ian E. L. Davis; Jennifer A Doudna; Alex Gorsky; Marillyn A.  Hewson; Hubert Joly; Mark B. McClellan; Anne M. Mulcahy; A.  Eugene Washinton; Mark A. Weinberger; Nadja Y. West; Ronald A. Williams; Darius Adamczyk

The current members of the Executive Committee of Johnson & Johnson are: Joaquin Duato; Vanessa Broadhurst; Peter Fasolo; William N. Hait; Mathai  Mammen; Ashley McEvoy; Thibaut Mongon; James Swanson; Jennifer Taubert;  Michael Ullman; Kathy Wengel; Joseph J. Wolk

On January 3, 2022, Joaquin Duato, became Chief Executive Officer. Alex Gorsky remains Executive Chairman.

3.

Reason and Request: The Infobox section has inaccuracies and is missing key content. Please consider replacing each section of the Infobox with the proposed replacement. Alex Gorsky is the Chairman. Joaquin Duato is the CEO. Paul Stoffels retired.

Update Industry

| industry = Pharmaceutical Medical Technology Consumer Healthcare

Update Key People

| key_people = {{Unbulleted list | Alex Gorsky {{small| (Chairman)}} | Joaquin Duato{{small| (CEO)}} }}
 * key_people = {{Unbulleted list

{{reflist-talk}} {{collapsed bottom}}